SARS-CoV-2/COVID-19 Prevalence Study

COVID-19 Prevention Network

Status

Completed

Conditions

COVID-19

Study type

Observational

Funder types

NETWORK

Identifiers

NCT04658121

CoVPN 5002

Details and patient eligibility

About

The COVID-19 Prevention Network (CoVPN) is doing a study to estimate the number of people who have or have had the SARS-CoV-2 virus in different communities in the United States. This study is being done to help determine the best places to perform future research studies that will test new drugs for treatment or prevention of COVID-19.

Full description

Design:

Cross-sectional surveys of (1) adults residing in senior living facilities and attending outpatient healthcare facilities, and (2) the general population in each selected research site community.

Population:

Adults residing in senior living facilities (nursing homes, assisted or independent living facilities) and attending outpatient healthcare facilities in neighborhoods of selected research sites
Adults and children (> 2 months of age) in neighborhoods of selected research sites

Study Size:

For each research site, up to 3,920 individuals will be enrolled from one, two, or all three of the following populations (must include at least community venues):

senior living facilities (nursing homes, assisted or independent living facilities; n = 500)
outpatient healthcare facilities (n = 500)
community venues distributed across four age categories (0-17, 18-39, 40-59, 60+ years) (n = 730 per stratum or 2920)

Total sample size = 3,920 x up to 20 clinical research sites

Study Duration:

Approximately sixteen (16) months for overall project. Two (2) months for protocol development and institutional review board (IRB) approval, followed by:

Facility-based surveys: 12 months (3 months for site preparation and initiation, 3 months for enrollment/sample collection, 4 months for shipping and laboratory testing*, 2 months for close-out), concurrent with
Time-location sampling (TLS) surveys: 14 months (3 months for site preparation and initiation, 6 months for enrollment/sample collection, 6 months for shipping and laboratory testing*, 2 months for close-out)
- Some activities will be concurrent with enrollment

Study Location:

Catchment areas surrounding US-based Clinical Research Sites (CRSs) of the: HIV Prevention Trials Network (HPTN), HIV Vaccine Trials Network (HVTN), Infectious Diseases Clinical Research Consortium (IDCRC), International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), and the AIDS Clinical Trials Group (ACTG); to be specified in the Site Announcement Memo

Study Methods:

Blood collection for SARS-CoV-2 antibody testing and characterization of the serologic response to SARS-CoV-2 infection; nasal mid-turbinate swab collection for SARS-CoV-2 RNA testing; collection of saliva in a subset of participants to evaluate the performance of diagnostic SARS-CoV-2 assays using these matrices; administration of tablet-based survey. Medical records abstraction for senior living facility participants who are unable to respond to the study survey.

Enrollment

26,741 patients

Sex

All

Ages

2+ months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Adults residing in senior living facilities or attending outpatient healthcare facilities:

At least 18 years of age
Willing and able to provide informed consent or consent has been provided by legal representative (for those with mental incapacity in senior living facilities)
Recruited from a selected facility

Adults and children from select neighborhoods of research site communities:

Adults and children > 2 months of age
For individuals < 18 years old, a guardian must be present (in person or by phone for those 15 - 17 years old)
Willing and able to provide consent (or assent for individuals 7-17 years old, parent/guardian will provide consent for all minors)
Recruited from a selected venue

Exclusion criteria

Previous enrollment in this study, either from the same or another CRS community.
Any condition that, in the opinion of the study staff, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives